Elicio Therapeutics Reports Inducement Grants

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 1,600 inducement stock options on March 16, 2026, to a newly hired employee under the 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have a strike price of $12.16 (Nasdaq closing price on March 16, 2026) and vest over four years with 25% vesting after one year and monthly ratable vesting thereafter, subject to continued service.

Key Figures

Option grant size: 1,600 options Option exercise price: $12.16 per share Vesting schedule: 4 years; 25% at 1 year +5 more

8 metrics

Option grant size 1,600 options Inducement stock options granted March 16, 2026

Option exercise price $12.16 per share Grant price equals Nasdaq close on March 16, 2026

Vesting schedule 4 years; 25% at 1 year Remainder vests monthly thereafter, subject to continued service

ATM capacity $100,000,000 At-the-market stock sales program under March 16, 2026 Sales Agreement

Shelf registration size $400,000,000 Form S-3/A shelf for mixed securities

Sales agent commission 3.0% Commission on gross proceeds under ATM Sales Agreement

Shares outstanding 17,800,307 shares As of December 31, 2025 cited in 424B5

Pre-news share price $12.16 Close used as option exercise price on March 16, 2026

Market Reality Check

Price: $12.18 Vol: Volume 102,507 is below t...

low vol

$12.18 Last Close

Volume Volume 102,507 is below the 20-day average of 152,344, suggesting limited trading interest ahead of this routine grant update. low

Technical Shares at $12.16 are trading above the 200-day MA of $9.35, indicating a pre-existing upward trend into this announcement.

Peers on Argus

ELTX slipped 0.33% while peers were mixed: NTHI up 0.67%, CCCC down 1.44%, IPHA ...

ELTX slipped 0.33% while peers were mixed: NTHI up 0.67%, CCCC down 1.44%, IPHA down 0.71%, SLS down 0.92%, and KYTX flat. This pattern points to stock-specific trading rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Mar 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Earnings and update	Neutral	+11.9%	Full-year 2025 financials and AMPLIFY-7P Phase 2 clinical update.
Feb 25	Conference appearance	Neutral	+10.3%	Announcement of TD Cowen healthcare conference presentation schedule.
Feb 18	Inducement grant	Neutral	+3.4%	30,300 inducement options granted at $8.59 under 2024 plan.
Jan 16	Inducement grant	Neutral	+5.6%	22,400 inducement options to two new employees at $7.81.
Dec 16	Inducement grant	Neutral	-4.3%	157,193 inducement options to three hires at $8.52.

Pattern Detected

Recent routine updates (conference, inducement grants) have often seen modest positive reactions, while one prior inducement grant drew a small negative move.

Recent Company History

Over the last few months, Elicio has alternated between corporate updates and routine HR-related equity grants. The March 12, 2026 full-year 2025 results and clinical update saw a 11.93% gain, while a TD Cowen conference appearance on February 25, 2026 lifted shares 10.35%. Multiple prior inducement grant announcements in December 2025, January 2026, and February 2026 produced mixed but generally modest price reactions. Today’s small inducement option grant fits this pattern of routine HR actions alongside larger financing and clinical milestones.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2026-03-12

$400,000,000 registered capacity

An effective Form S-3/A shelf filed on March 12, 2026 allows Elicio to issue up to $400,000,000 of securities, including common stock, preferred stock, debt, warrants and units, via future prospectus supplements. A separate at-the-market program enables sales of up to $100,000,000 of common stock through designated agents for funding clinical development and corporate purposes.

Market Pulse Summary

This announcement details a small inducement grant of 1,600 stock options at $12.16 per share under ...

Analysis

This announcement details a small inducement grant of 1,600 stock options at $12.16 per share under Elicio’s 2024 Inducement Incentive Award Plan, vesting over four years with a standard 25% cliff. It follows a series of similar grants over recent months, indicating a consistent approach to equity-based hiring. In parallel, investors may track the company’s broader capital structure, including its $400,000,000 shelf and $100,000,000 ATM program, alongside upcoming clinical and financial milestones.

Key Terms

inducement stock options, Nasdaq Listing Rule 5635(c)(4), Inducement Incentive Award Plan

3 terms

inducement stock options financial

"Elicio granted an aggregate of 1,600 inducement stock options to a new employee"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

Inducement Incentive Award Plan financial

"granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan"

An inducement incentive award plan is a package of stock-based pay—like options or restricted shares—given to a newly hired executive or key employee to persuade them to join a company. It matters to investors because such awards can spread ownership thinner and create a cost on the company’s financial statements, while also aligning the new hire’s performance with shareholder value much like a signing bonus that ties future pay to company results.

AI-generated analysis. Not financial advice.

BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on March 16, 2026, Elicio granted an aggregate of 1,600 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

The grant provides for the purchase of shares of Elicio common stock at a price of $12.16 per share, the closing price per share of Elicio common stock as reported by Nasdaq on March 16, 2026, the date of grant.

The grant vests over four years, with 25 percent of the shares vesting on the first anniversary of the employee’s start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Elicio intends to expand ELI-002 7P clinical development not only for treatment in adjuvant pancreatic ductal adenocarcinoma, but also in neoadjuvant and metastatic pancreatic ductal adenocarcinoma (“PDAC”) settings, and for other mKRAS-positive cancers. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive PDAC who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

What did Elicio Therapeutics (ELTX) announce on March 17, 2026 about inducement grants?

Elicio announced an aggregate grant of 1,600 inducement stock options on March 16, 2026. According to the company, the grants were approved by the Compensation Committee and issued under the 2024 Inducement Incentive Award Plan per Nasdaq rule 5635(c)(4).

What is the exercise price and grant date for ELTX inducement options granted March 16, 2026?

The exercise price is $12.16 per share, equal to Nasdaq’s closing price on March 16, 2026. According to the company, the grant date was March 16, 2026 and the price matches the reported closing price that day.

How do the ELTX inducement options vest for the new employee?

The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. According to the company, vesting is contingent on the employee’s continued service through applicable vesting dates.

Why did Elicio grant inducement stock options under Nasdaq Listing Rule 5635(c)(4)?

The grants were issued as an inducement to new employment in compliance with Nasdaq Listing Rule 5635(c)(4). According to the company, this rule permits issuance of awards to attract a newly hired employee, subject to committee approval and plan terms.